Article
Oncology
Jaleesa Moore, Fei Wang, Tuya Pal, Sonya Reid, Hui Cai, Christina E. Bailey, Wei Zheng, Loren Lipworth, Xiao-Ou Shu
Summary: This study found disparities in the uptake of ODX RS testing and risk distribution among different race/ethnicity groups. However, ODX RS was prognostic for overall mortality across all races/ethnicities, particularly in younger patients.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Joshua A. Bloom, Yurie Sekigami, Rebekah Young, Lisa Macera, Christy A. Russell, Yu Cao, Rachel J. Buchsbaum, Stephen P. Naber, Abhishek Chatterjee
Summary: This study demonstrates that a clinically significant rate of discordance in Oncotype DX results among patients with bilateral breast cancer may impact discussions regarding chemotherapy treatment.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Ran Cheng, Zhongzhao Wang, Xiangyi Kong, Jing Wang, Yi Fang, Liqiang Qi
Summary: In this study, a method was developed to provide a single score for patients with hormone receptor-positive, HER2-negative, node-negative breast cancer and midrange Oncotype DX breast recurrence scores, aiming to individualize chemotherapy treatment decisions. The analysis showed that chemotherapy benefit was associated with specific tumor characteristics for patients with RS = 16-25, suggesting personalized chemotherapy recommendations can be made based on these factors.
Article
Oncology
Richard Buus, Ivana Sestak, Ralf Kronenwett, Sean Ferree, Catherine A. Schnabel, Frederick L. Baehner, Elizabeth A. Mallon, Jack Cuzick, Mitch Dowsett
Summary: The molecular features driving Oncotype DX, Prosigna PAM50, EndoPredict, and Breast Cancer Index are identified, with varying degrees of correlation between the molecular scores. While RS is more influenced by estrogen-related features, EP, BCI, and ROR scores are largely determined by proliferative features.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Michelle Zhang, Meredith Sadinski, Dana Haddad, Min Sun Bae, Danny Martinez, Elizabeth A. Morris, Peter Gibbs, Elizabeth J. Sutton
Summary: The study revealed an association between BPE metrics in the non-tumor breast and tumor Oncotype Dx recurrence score, suggesting a potential relationship between the breast microenvironment and likelihood of recurrence and response to chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Summary: This study evaluates whether Oncotype DX improves confidence and agreement among oncologists in adjuvant chemotherapy recommendations for ER+/HER2- early-stage breast cancers. The study found that using Oncotype DX significantly reduces discordance and uncertainty among oncologists, and improves agreement in adjuvant chemotherapy recommendations for patients.
Article
Oncology
Ran Song, Dong-Eun Lee, Eun-Gyeong Lee, Seeyoun Lee, Han-Sung Kang, Jai Hong Han, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Youngmee Kwon, Jaeyeon Woo, So-Youn Jung
Summary: This retrospective study identified clinicopathological factors that can predict the Oncotype DX (ODX) risk group in early breast cancer patients, providing alternative options to the costly and time-consuming ODX test. The factors predicting the ODX risk group differ according to age, and can help guide decision-making on adjuvant chemotherapy.
Article
Oncology
Xiaofu Zhu, Susan Dent, Lise Paquet, Tinghua Zhang, Daniel Tesolin, Nadine Graham, Olexiy Aseyev, Xinni Song
Summary: Canadian medical oncologists preferentially use the ODX assay to avoid unnecessary chemotherapy for breast cancer patients, especially those with intermediate clinical and pathologic features.
Article
Oncology
Vikram R. Shaw, Christopher I. Amos, Chao Cheng
Summary: In this study, a machine learning method is applied to determine the optimal threshold for using the Oncotype DX score to guide chemotherapy treatment. The results show that more lymph-node-negative and lymph-node-positive patients may benefit from chemotherapy at a lower Oncotype DX score than current guidelines suggest. Additionally, the study reveals a racial difference in chemotherapy benefit, providing evidence for tailored treatment for specific patients.
Article
Oncology
Caglar Unal, Tolga Ozmen, Cetin Ordu, Kezban Nur Pilanci, Ahmet Serkan Ilgun, Erhan Gokmen, Elvina Almuradova, Mustafa Ozdogan, Niluefer Guler, Cihan Uras, Halil Kara, Orhan Demircan, Selver Isik, Gul Alco, Pinar Saip, Esra Aydin, Tomris Duymaz, Filiz Celebi, Kanay Yararbas, Gursel Soybir, Vahit Ozmen
Summary: This study aimed to evaluate survival and its correlation with ODx-RS in pT1-2, N0-N1mic patients treated with adjuvant therapy. The findings suggest that the addition of chemotherapy to endocrine therapy improves disease-free survival in patients aged <= 45 years with ODx-RS scores of >= 18.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Valeria Romeo, Renato Cuocolo, Luca Sanduzzi, Vincenzo Carpentiero, Martina Caruso, Beatrice Lama, Dimitri Garifalos, Arnaldo Stanzione, Simone Maurea, Arturo Brunetti
Summary: In this study, a machine learning model was developed to predict the Oncotype DX score using DCE-MRI images of breast cancer patients. The model achieved an accuracy of 60% in the training set and 63% (AUC = 0.66) in the test set. These findings support the use of radiomics and machine learning for prognostic data prediction in breast cancer, with potential clinical applications.
Article
Oncology
Arya Mariam Roy, Changchuan Jiang, Stuthi Perimbeti, Lei Deng, Charles L. Shapiro, Shipra Gandhi
Summary: This study examined the interaction between HER2-low expression, oncotype recurrence score (RS), and prognosis in HR+/HER2- breast cancer. The results showed that HER2-low tumors had higher RS distribution and better 5-year overall survival compared to HER2-zero tumors, especially in HR-negative patients and those who received adjuvant chemotherapy.
Article
Oncology
Rachel M. Layman, Heather Lin, Angelica M. Gutierrez Barrera, Meghan S. Karuturi, Clinton Yam, Banu K. Arun
Summary: BRCA-associated early-stage hormone receptor-positive breast cancers have distinctive features compared to those without mutations. However, BRCA status does not significantly impact relapse-free survival and overall survival.
Article
Oncology
Rima Patel, Malin Hovstadius, Melanie W. Kier, Erin L. Moshier, Brittney S. Zimmerman, Krystal Cascetta, Shabnam Jaffer, Joseph A. Sparano, Amy Tiersten
Summary: There is no significant correlation between Ki67 and Oncotype DX RS in early-stage hormone receptor-positive breast cancer patients, although there is fair agreement between high Ki67 values and high RS values.
Article
Oncology
Jaime A. Pardo, Betty Fan, Alessandra Mele, Stephanie Serres, Monica G. Valero, Isha Emhoff, Amulya Alapati, Ted A. James
Summary: This study found that Oncotype DX(R) RS can serve as an independent predictor for axillary pathologic complete response in ER +/HER2 - breast cancer patients receiving neoadjuvant chemotherapy. A greater proportion of patients with a high RS achieved axillary pCR, supporting the use of Oncotype DX(R) as a tool to improve clinical decision making in axillary management.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Solange Bayard, Laura Susick, Ishmael Kyei, Yalei Chen, Melissa B. Davis, Kofi Gyan, Lisa A. Newman
AMERICAN JOURNAL OF SURGERY
(2020)
Article
Oncology
Jung S. Byun, Sandeep K. Singhal, Samson Park, Dae Ik Yi, Tingfen Yan, Ambar Caban, Alana Jones, Partha Mukhopadhyay, Sara M. Gil, Stephen M. Hewitt, Lisa Newman, Melissa B. Davis, Brittany D. Jenkins, Jorge L. Sepulveda, Adriana De Siervi, Anna Maria Napoles, Nasreen A. Vohra, Kevin Gardner
CLINICAL CANCER RESEARCH
(2020)
Letter
Surgery
Yalei Chen, Laura Susick, Melissa Davis, Jessica Bensenhaver, S. David Nathanson, Jessica Burns, Lisa A. Newman
Article
Pathology
Mansour A. Alsaleem, Graham Ball, Michael S. Toss, Sara Raafat, Mohammed Aleskandarany, Chitra Joseph, Angela Ogden, Shristi Bhattarai, Padmashree C. G. Rida, Francesca Khani, Melissa Davis, Olivier Elemento, Ritu Aneja, Ian O. Ellis, Andrew Green, Nigel P. Mongan, Emad Rakha
Article
Pathology
Pavithra Dedigama-Arachchige, Shannon Carskadon, Jia Li, Ian Loveless, Mohamed Alhamar, James O. Peabody, Hans Stricker, Dhananjay A. Chitale, Craig G. Rogers, Mani Menon, Nilesh S. Gupta, Tarek A. Bismar, Sean R. Williamson, Nallasivam Palanisamy
Article
Oncology
Melissa Davis, Rachel Martini, Lisa Newman, Olivier Elemento, Jason White, Akanksha Verma, Indrani Datta, Indra Adrianto, Yalei Chen, Kevin Gardner, Hyung-Gyoon Kim, Windy D. Colomb, Isam-Eldin Eltoum, Andra R. Frost, William E. Grizzle, Andrea Sboner, Upender Manne, Clayton Yates
Article
Pathology
Mohamed Alhamar, Bassam Alkamachi, Harshita Mehrotra, Jessica Sanchez, Haythem Ali, Daniel Schultz, Dhananjay A. Chitale
Summary: The study aimed to determine the distribution and prognosis of HER2 groups in invasive breast cancers using updated ASCO-CAP guidelines. Results showed that HER2 FISH categories were significantly associated with overall survival and disease-specific survival in breast cancer patients, with high HER2 amplification patients benefiting more.
Review
Oncology
Rachel Martini, Lisa Newman, Melissa Davis
Summary: Breast cancer mortality is 40% higher among African American women compared to their White counterparts in the US, primarily driven by tumor characteristics rather than socio-economic factors. Despite similar incidence rates, African American women still have higher mortality rates across all breast cancer subtypes.
CLINICAL & EXPERIMENTAL METASTASIS
(2022)
Article
Oncology
Benjamin Holmes, Dhananjay Chitale, Joshua Loving, Mary Tran, Vinod Subramanian, Anna Berry, Matthew Rioth, Raghu Warrier, Thomas Brown
Summary: The study introduces a novel method that incorporates terminology-driven semantic tags into a task-specific semantic frame to enhance MetaMap with necessary context for capturing important contextual information in pathology reports related to biomarker results.
JCO CLINICAL CANCER INFORMATICS
(2021)
Article
Medicine, General & Internal
Thomas E. Rohan, Mindy Ginsberg, Yihong Wang, Fergus J. Couch, Heather S. Feigelson, Robert T. Greenlee, Stacey Honda, Azadeh Stark, Dhananjay Chitale, Tao Wang, Xiaonan Xue, Maja H. Oktay, Joseph A. Sparano, Olivier Loudig
Summary: This study aims to identify patients with DCIS at risk of developing IBC using risk factor data and FFPE DCIS tissue, as well as evaluating the associations between miRNA expression changes, marker sets, and risk factors with subsequent IBC development in a large cohort of women.
Article
Oncology
Benjamin A. Rybicki, Sudha M. Sadasivan, Yalei Chen, Ian Loveless, Nilesh S. Gupta, Dhananjay A. Chitale, Sean R. Williamson, Andrew G. Rundle, Deliang L. Tang
Summary: This study found that White men have longer telomeres in benign prostate tissue, and longer telomeres may be associated with increased risk for prostate cancer, particularly the more aggressive form of the disease.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Daisy B. Haigh, Corinne L. Woodcock, Jennifer Lothion-Roy, Anna E. Harris, Veronika M. Metzler, Jenny L. Persson, Brian D. Robinson, Francesca Khani, Mansour Alsaleem, Atara Ntekim, Srinivasan Madhusudan, Melissa B. Davis, Kristian B. Laursen, Lorraine J. Gudas, Catrin S. Rutland, Michael S. Toss, Nathan Archer, Zsuzsanna Bodi, Emad A. Rakha, Rupert G. Fray, Jennie N. Jeyapalan, Nigel P. Mongan
Summary: This study investigated whether therapies targeting the epitranscriptome can suppress androgen signalling in prostate cancer. The results showed that METTL3 is aberrantly expressed in prostate cancer patients and that knockdown or inhibition of METTL3 can significantly alter the basal and androgen-regulated transcriptome in prostate cancer, suggesting that targeting m6A could be a novel approach to modulate androgen signalling in prostate cancer.
Article
Oncology
Md Shakir Uddin Ahmed, Brittany D. Lord, Benjamin Adu Addai, Sandeep K. Singhal, Kevin Gardner, Ahmad Bin Salam, Anghesom Ghebremedhin, Jason White, Iqbal Mahmud, Rachel Martini, Deepa Bedi, Huixian Lin, Jacqueline D. Jones, Balasubramanyanam Karanam, Windy Dean-Colomb, William Grizzle, Honghe Wang, Melissa Davis, Clayton C. Yates
Summary: African American women with breast cancer have higher inflammation and a stronger immune response than European American women. The biological role of Kaiso in immune signaling was demonstrated in breast cancer exosomes. Kaiso depletion reduced tumor formation and increased infiltration of M1 macrophages.
Review
Physics, Condensed Matter
Melissa Davis, Zhibin Yu
JOURNAL OF SEMICONDUCTORS
(2020)
Meeting Abstract
Oncology
Rachel Martini, Lisa Newman, Nancy Manley, Melissa Davis
